Tybourne Capital Management (hk) Ltd.
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 1, 2025), Tybourne Capital Management (hk) Ltd. reported 6 stock positions worth $34.5 million. Its top holding was Forte Biosciences (FBRX) at 29.4% of the portfolio, followed by Taysha Gene Therapies (TSHA, 27.4%) and Bicycle Therapeutics PLC-ADR (BCYC, 20.0%). Compared with Q1 2025, it opened 2 new positions, sold out of 1 and added to 4. The biggest buy was a new position in Alumis (ALMS) and the biggest sale an exit from Acelyrin (SLRN).
- Most Recent 13F
- Q3 2025
- Location
- HONG KONG, K3
- CIK
- 0001553936
- Portfolio Value
- $34.5M (Q2 2025)
- SEC Filing
- 0001553936-25-000011 ↗ filed Aug 1, 2025
Holdings Value
Holdings 6 stocks · $34.5M
| FBRX Forte Biosciences Inc. | 29.45% | 786,647 | $10.2M | Add +26.9% |
| TSHA Taysha Gene Therapies Inc. | 27.39% | 4,095,000 | $9.5M | Add +10.7% |
| BCYC Bicycle Therapeutics PLC-ADR | 20.00% | 993,743 | $6.9M | Add +72.4% |
| ALMS Alumis Inc. | 12.15% | 1,399,250 | $4.2M | New |
| MBUU Malibu Boats Inc. Class A | 6.05% | 66,705 | $2.1M | New |
| ZNTL Zentalis Pharmaceuticals Inc. | 4.96% | 1,478,152 | $1.7M | Add +53.7% |
Portfolio Sells Q1 2025 → Q2 2025
| SLRN Acelyrin Inc. | Sold out | 0.00% | −30.48 |
Portfolio Buys Q1 2025 → Q2 2025
| ALMS Alumis Inc. | New | 12.15% | +12.15 |
| FBRX Forte Biosciences Inc. | Add +26.9% | 29.45% | +9.02 |
| MBUU Malibu Boats Inc. Class A | New | 6.05% | +6.05 |
| TSHA Taysha Gene Therapies Inc. | Add +10.7% | 27.39% | +5.55 |
| BCYC Bicycle Therapeutics PLC-ADR | Add +72.4% | 20.00% | −0.78 |
| ZNTL Zentalis Pharmaceuticals Inc. | Add +53.7% | 4.96% | −1.53 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q3 2025 | 4 | $30.9M | TSHA, FBRX, ALMS, ZNTL |
| Q2 2025 | 6 | $34.5M | FBRX, TSHA, BCYC, ALMS, MBUU |
| Q1 2025 | 5 | $23.6M | SLRN, TSHA, BCYC, FBRX, ZNTL |
| Q4 2024 | 33 | $398.4M | CP, IQV, ADSK, EPAM, LPLA |
| Q3 2024 | 32 | $356.7M | TXN, CP, LPLA, EPAM, IQV |
| Q2 2024 | 36 | $491.7M | TXN, CP, ZG, EPAM, IQV |
| Q1 2024 | 38 | $584.9M | CP, TXN, IQV, LIN, BCYC |